Publications by authors named "Genia Long"

Claim this Profile
T
The Impact of the Inflation Reduction Act's Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs.
Robert J Nordyke, Julie A Patterson, James Motyka, Benjamin March, Noam Y Kirson, Genia Long

Value Health· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncology Drugs: The Authors Reply.
Henry Grabowski, Joseph A DiMasi, Genia Long

Health Aff (Millwood)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postapproval Innovation For Oncology Drugs And The Inflation Reduction Act.
Henry Grabowski, Joseph A DiMasi, Genia Long

Health Aff (Millwood)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction Act.
Henry Grabowski, Genia Long

J Med Econ· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuing trends in U.S. brand-name and generic drug competition.
Henry Grabowski, Genia Long, Richard Mortimer, Mehmet Bilginsoy

J Med Econ· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Financing Drug Innovation in the US: Current Framework and Emerging Challenges.
David Cutler, Noam Kirson, Genia Long

Pharmacoeconomics· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Federal government-interest patent disclosures for recent top-selling drugs.
Genia Long

J Med Econ· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insurance switching and mismatch between the costs and benefits of new technologies.
David Cutler, Michael Ciarametaro, Genia Long, Noam Kirson, Robert Dubois

Am J Manag Care· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated trends in US brand-name and generic drug competition.
Henry Grabowski, Genia Long, Richard Mortimer, Ani Boyo

J Med Econ· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.
Iain Cockburn, Genia Long

Expert Opin Ther Pat· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The roles of patents and research and development incentives in biopharmaceutical innovation.
Henry G Grabowski, Joseph A DiMasi, Genia Long

Health Aff (Millwood)· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving provider payment models and patient access to innovative medical technology.
Genia Long, Richard Mortimer, Geoffrey Sanzenbacher

J Med Econ· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent trends in brand-name and generic drug competition.
Henry Grabowski, Genia Long, Richard Mortimer

J Med Econ· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies.
Anna Kaltenboeck, Genia Long, Eleanor Hayes-Larson, Gilberto de Lima Lopes

Expert Rev Clin Pharmacol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
Henry G Grabowski, Margaret Kyle, Richard Mortimer, Genia Long, Noam Kirson

Health Aff (Millwood)· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of the biosimilar pathway: economic and policy issues.
Henry Grabowski, Genia Long, Richard Mortimer

Seton Hall Law Rev· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commercial importation of prescription drugs in the United States: short-run implications.
Patricia M Danzon, Scott J Johnson, Genia Long, Michael F Furukawa

J Health Polit Policy Law· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data exclusivity for biologics.
Henry Grabowski, Genia Long, Richard Mortimer

Nat Rev Drug Discov· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value of antihypertensive drugs: a perspective on medical innovation.
David M Cutler, Genia Long, Ernst R Berndt, Jimmy Royer, Andrée-Anne Fournier

Health Aff (Millwood)· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The market for follow-on biologics: how will it evolve?
Henry Grabowski, Iain Cockburn, Genia Long

Health Aff (Millwood)· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis